Adjuvant Tx HER2 Negative EBC
Adjuvant Therapy for HER2-Negative Early Breast Cancer: Interactive Decision Support Tool

Released: August 22, 2024

Expiration: August 21, 2025

Instructions

This Interactive Decision Support Tool provides adjuvant therapy recommendations for patients with HER2-negative early breast cancer from 5 experts based on the specific patient and disease characteristics you enter. It is recommended that you have as much information as possible available before you begin.

You first will be asked for the patient’s hormone receptor (HR) status (eg, triple negative [TNBC] or HR positive), and you then will be prompted to provide specific information about the patient, such as:

  • TNBC only: disease stage, type of neoadjuvant chemotherapy, pathologic complete response status, germline BRCA status, eligibility for adjuvant olaparib per the TNBC cohort in the OlympiA trial
  • HR positive only: planned adjuvant chemotherapy, planned adjuvant endocrine therapy, germline BRCA status, eligibility for adjuvant abemaciclib plus endocrine therapy per the FDA-approved indication, eligibility for adjuvant olaparib per the HR-positive cohort in the OlympiA trial

Click on your selections. Your choices can be changed at any time simply by selecting the [change] icon by the question you want to change and entering a new choice.

Additional information on each variable/characteristic and why it is important for making adjuvant therapy decisions is available by clicking on the [i] icon after each selection.

When all patient characteristics are entered, you will be asked to select the management option you are currently planning. Once that information is entered, you can click on Submit Patient Case to view the expert recommendations.

After reviewing your case-specific recommendations, you will be asked brief questions about how the recommendations influenced your decision-making. You will then be able to enter a new case scenario by clicking the Start New Case button.

Access to and use of this Interactive Decision Support Tool titled, “Adjuvant Therapy for HER2-Negative Early Breast Cancer: Interactive Decision Support Tool,” is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.

This Interactive Decision Support Tool is designed to educate healthcare professionals on making optimal adjuvant therapy choices for treating individuals with HER2-negative early breast cancer who have already undergone surgery and, if applicable, are already receiving adjuvant endocrine therapy. The information provided is based on the expert guidance of Kevin Kalinsky, MD, MS; Laura A. Huppert, MD; Reshma L. Mahtani, DO; Laura M. Spring, MD; and Tiffany A. Traina, MD, FASCO.

The material published by Clinical Care Options reflects the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the FDA. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Although the information contained in the “Adjuvant Therapy for HER2-Negative Early Breast Cancer: Interactive Decision Support Tool” has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. This disclaimer applies to both the isolated and aggregate uses of the information. Clinical Care Options provides this information on an as-is basis. This disclaimer applies to all material published by Clinical Care Options, including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights, are disclaimed.

Any trademarks are the property of respective companies.

© 2024 Clinical Care Options, LLC. All rights reserved.

Program Content